☆ 4.5 Meeting Abstract

Safety, tolerability, pharmacokinetics and metabolism of balovaptan, a selective vasopressin 1a receptor antagonist, in healthy subjects

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2019)

Get Full Text
Add to Collection

Journal

EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 29, Issue -, Pages S162-S162

Publisher

ELSEVIER
DOI: 10.1016/j.euroneuro.2019.09.253

Keywords

-

Categories

Clinical Neurology Neurosciences Pharmacology & Pharmacy Psychiatry

Funding

  1. F. Hoffmann-La Roche Ltd

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.